Patents by Inventor Richard M. Hyde

Richard M. Hyde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmacologically active CNS compounds
    Patent number: 5635507
    Abstract: A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 3, 1997
    Assignee: Glaxo Wellcome Inc.
    Inventors: Alistair A. Miller, Malcolm S. Nobbs, Richard M. Hyde, Michael J. Leach
  • Treatment of injury of the spinal cord or brain using 4-amino-2-(4-methylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)pyrimidine
    Patent number: 5597827
    Abstract: A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 28, 1997
    Inventors: Alistair A. Miller, Malcolm S. Nobbs, Richard M. Hyde, Michael J. Leach
  • Certain 2,4-diamino-5-(2,3-dihalophenyl)-6-substituted pyrimidines which are pharmacologically active CNS compounds
    Patent number: 5597828
    Abstract: A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 28, 1997
    Assignee: Glaxo Wellcome Inc.
    Inventors: Alistair A. Miller, Malcolm S. Nobbs, Richard M. Hyde, Michael J. Leach
  • Treatment of damage from a stroke using 4-amino(4-methylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)pyrimidine
    Patent number: 5591746
    Abstract: A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 7, 1997
    Inventors: Alistair A. Miller, Malcolm S. Nobbs, Richard M. Hyde, Michael J. Leach
  • Certain 2,4-diamino-5-(2,3,5-TRI-chlorophenyl)-6-substituted-pyrimidines which are pharmacologically active CNS compounds
    Patent number: 5587380
    Abstract: A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 24, 1996
    Assignee: Glaxo Wellcome Inc.
    Inventors: Alistair A. Miller, Malcolm S. Nobbs, Richard M. Hyde, Michael J. Leach
  • Nitrile compounds
    Patent number: 5136080
    Abstract: A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.
    Type: Grant
    Filed: June 5, 1990
    Date of Patent: August 4, 1992
    Assignee: Burroughs Wellcome Co.
    Inventors: Alistair A. Miller, Malcolm S. Nobbs, Richard M. Hyde, Michael John
  • Tetrazolyl substituted tricyclic compounds and pharmacological compositions thereof
    Patent number: 4902701
    Abstract: Tricyclic compounds of formula (I) ##STR1## wherein X.sup.1 is a carboxyl or 5-tetrazolyl groupX.sup.2 is carbonyl or methyleneX.sup.3 is hydroxyl or a group --X.sup.4 (C.sub.n H.sub.2n)X.sup.5whereX.sup.4 is oxygen or sulphurX.sup.5 is hydrogen or a group --OX.sup.6whereX.sup.6 is hydrogen, alkanoyl of 1 to 4 carbon atoms or a group --(C.sub.m H.sub.2m)X.sup.7whereX.sup.7 is hydrogen or a group --OX.sup.8whereX.sup.8 is hydrogen or alkanoyl of 1 to 4 carbon atoms and m and n are each, independently, an integer from 1 to 4, together with salts thereof,provided that when X.sup.5 is a group --OX.sup.6 then n is always greater than 1 and X.sup.4 and X.sup.5 are attached to different carbon atomsand that when X.sup.7 is a group --OX.sup.8 then m is always greater than 1 and no single carbon atom in the radical --(C.sub.m H.sub.2m)-- is attached to two oxygen atoms.
    Type: Grant
    Filed: September 3, 1986
    Date of Patent: February 20, 1990
    Assignee: Burroughs Welcome Co.
    Inventors: John F. Batchelor, Richard M. Hyde, Williasm R. King, David J. Livingstone
  • Pharmacologically active ketones and use
    Patent number: 4791136
    Abstract: Use of compounds of formula (I) ##STR1## to provide a more effective delivery of oxygen to the tissues of a mammalian, including human, recipient.In vivo applications include the relief or amelioration of conditions wherein there is tissue hypoxia; in vitro the compounds are of use in the storage of mammalian, including human, red blood cells to maintain their oxygen-delivery capacity and prolong their useful storage life.Also provided is a sterile, sealed vessel containing an anticoagulant, a non-toxic amount of a compound of formula (I) and optionally mammalian, in particular human, red blood cells.
    Type: Grant
    Filed: July 30, 1986
    Date of Patent: December 13, 1988
    Assignee: Burroughs Wellcome Co.
    Inventors: John F. Batchelor, Richard M. Hyde, David J. Livingstone
  • Storage of red blood cells
    Patent number: 4626431
    Abstract: Use of compounds of formula (I) ##STR1## to provide a more effective delivery of oxygen to the tissues of a mammalian, including human, recipient.In vivo applications include the relief or amelioration of conditions wherein there is tissue hypoxia; in vitro the compounds are of use in the storage of mammalian, including human, red blood cells to maintain their oxygen-delivery capacity and prolong their useful storage life.Also provided is a sterile, sealed vessel containing an anticoagulant, a non-toxic amount of a compound of formula (I) and optionally mammalian, in particular human, red blood cells.
    Type: Grant
    Filed: October 19, 1984
    Date of Patent: December 2, 1986
    Assignee: Burroughs Wellcome Co.
    Inventors: John F. Batchelor, Richard M. Hyde, David J. Livingstone
  • Storage of red blood cells
    Patent number: 4626432
    Abstract: Use of compounds of formula (I) ##STR1## to provide a more effective delivery of oxygen to the tissues of a mammalian, including human, recipient.In vivo applications include the relief or amelioration of conditions wherein there is tissue hypoxia; in vitro the compounds are of use in the storage of mammalian, including human, red blood cells to maintain their oxygen-delivery capacity and prolong their useful storage life.Also provided is a sterile, sealed vessel containing an anticoagulant, a non-toxic amount of a compound of formula (I) and optionally mammalian, in particular human, red blood cells.
    Type: Grant
    Filed: October 19, 1984
    Date of Patent: December 2, 1986
    Assignee: Burroughs Wellcome Co.
    Inventors: Richard M. Hyde, David J. Livingstone